^
Association details:
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
Title:

Soluble forms of PD-L1 and PD-1 as prognostic and predictive markers of sunitinib efficacy in patients with metastatic clear cell renal cell carcinoma

Published date:
11/25/2020
Excerpt:
mccRCC patients with high plasmatic levels of sPD-L1 or sPD-1 are poor responders to sunitinib.
DOI:
10.1080/2162402X.2020.1846901